Top Ten most popular articles on Pharmafile.com this week
With the weekend on the horizon and a new issue of Pharmafocus hitting press, we review the most read, shared and discussed topics featured on our website this week.
It's been a big week for trial data and drug approvals, though not all of the news is positive: while Parkinson's patients can celebrate the first new FDA-approved treatment in a decade, Novartis licks its wounds over the borken promise of its heart failure drug serelaxin, which tanked in Phase 3 trials. But perhaps the most shocking newss this week was the emergent link found between the use of a popular hormone pregnancy test and potential birth defects.
Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody for the treatment of early Alzheimer’s disease.
Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of patients maintained clear skin for one year without treatment. The benefits were even seen to continue after two years in 10% of patients.
Array BioPharma has announced that it has pulled its new drug application (NDA) for its drug, binimetinib, for the treatment of NRAS-mutant melanoma. The drug was found to display only marginal efficacy over standard treatment.
An unsettling new investigation has revealed a potential cover-up of birth defects linked to a hormone pregnancy test, with echoes of the thalidomide babies case of the 1950s.
The FDA has approved Xadago (safinamide) as a supplementary treatment for Parkinson’s in patients currently taking levodopa/carbidopa and who are also experiencing bouts of ineffectiveness of these medications.
AstraZeneca's hyperkalaemia drug has been hit with a second rejection by the FDA in the course of a year due to manufacturing issues in the production of ZS-9.
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, 2016 was the year where it really came to the fore. We examine the leading immunotherapies in the market and their development as we move further into 2017.
GSK has officially broken ground on the expansion of its site in County Durham. The expanded site will be an aseptic sterile facility that will make liquid biopharmaceuticals, located at its manufacturing base at Barnard Castle.
A study emerging from Denmark has found that the use of over-the-counter pain killer, Ibuprofen, is associated with an increased risk of cardiac arrest. Research found an increase of 31% in cardiac arrest risk through the use of the anti-inflammatory.
It looks like the once promising future for serelaxin may be in tatters, as it failed to impress in a Phase 3 trial to reduce cardiovascular death or worsening heart failure in patients with acute heart failure.